Cingulate Inc. – NASDAQ:CING
Cingulate stock price today
Cingulate stock price monthly change
Cingulate stock price quarterly change
Cingulate stock price yearly change
Cingulate key metrics
Market Cap | 14.55M |
Enterprise value | 6.93M |
P/E | -0.67 |
EV/Sales | N/A |
EV/EBITDA | -0.39 |
Price/Sales | N/A |
Price/Book | 2.94 |
PEG ratio | -0.04 |
EPS | -22.68 |
Revenue | N/A |
EBITDA | -30.22M |
Income | -22.50M |
Revenue Q/Q | -100% |
Revenue Y/Y | -200% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCingulate stock price history
Cingulate stock forecast
Cingulate financial statements
| Jun 2023 | 0 | -6.61M | |
|---|---|---|---|
| Sep 2023 | 0 | -5.97M | |
| Dec 2023 | -3.84B | -6.93M | 0.18% |
| Mar 2024 | 0 | -2.97M |
| Mar 2024 | 0 | -2.97M | |
|---|---|---|---|
| Sep 2025 | 0 | -1.10M | |
| Oct 2025 | 0 | -3.01M | |
| Dec 2025 | 0 | -2.96M |
Analysts Price target
Financials & Ratios estimates
| 2023-11-13 | -4.8 | -6 |
|---|---|---|
| 2024-04-05 | -2.6 | -8.2 |
| 2024-05-08 | -2.2 | -0.6 |
| Jun 2023 | 5227447 | 11.32M | 216.66% |
|---|---|---|---|
| Sep 2023 | 5870258 | 5.96M | 101.64% |
| Dec 2023 | 3491436 | 10.36M | 296.75% |
| Mar 2024 | 5494515 | 2.27M | 41.47% |
| Jun 2023 | -4.60M | -1 | 3.21M |
|---|---|---|---|
| Sep 2023 | -4.29M | 0 | 5.92M |
| Dec 2023 | -2.56M | -186.96K | 815.43K |
| Mar 2024 | -8.74M | -81.50K | 9.88M |
Cingulate alternative data
| Aug 2023 | 15 |
|---|---|
| Sep 2023 | 15 |
| Oct 2023 | 15 |
| Nov 2023 | 15 |
| Dec 2023 | 15 |
| Jan 2024 | 15 |
| Feb 2024 | 15 |
| Mar 2024 | 15 |
| Apr 2024 | 15 |
| May 2024 | 13 |
| Jun 2024 | 13 |
| Jul 2024 | 13 |
Cingulate other data
| Period | Buy | Sel |
|---|---|---|
| Nov 2022 | 94703 | 0 |
| Dec 2022 | 65720 | 0 |
| May 2023 | 7030 | 0 |
| Aug 2023 | 1823155 | 0 |
| Sep 2023 | 5000 | 0 |
-
What's the price of Cingulate stock today?
One share of Cingulate stock can currently be purchased for approximately $3.78.
-
When is Cingulate's next earnings date?
Unfortunately, Cingulate's (CING) next earnings date is currently unknown.
-
Does Cingulate pay dividends?
No, Cingulate does not pay dividends.
-
How much money does Cingulate make?
Cingulate has a market capitalization of 14.55M. Cingulate made a loss 23.53M US dollars in net income (profit) last year or -$0.6 on an earnings per share basis.
-
What is Cingulate's stock symbol?
Cingulate Inc. is traded on the NASDAQ under the ticker symbol "CING".
-
What is Cingulate's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cingulate?
Shares of Cingulate can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Cingulate have?
As Jul 2024, Cingulate employs 13 workers, which is 13% less then previous quarter.
-
When Cingulate went public?
Cingulate Inc. is publicly traded company for more then 3 years since IPO on 8 Dec 2021.
-
What is Cingulate's official website?
The official website for Cingulate is cingulate.com.
-
Where are Cingulate's headquarters?
Cingulate is headquartered at 1901 West 47th Place, Kansas City, KS.
-
How can i contact Cingulate?
Cingulate's mailing address is 1901 West 47th Place, Kansas City, KS and company can be reached via phone at +91 39422300.
Cingulate company profile:
Cingulate Inc.
cingulate.comNASDAQ
13
Biotechnology
Healthcare
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Kansas City, KS 66205
CIK: 0001862150
ISIN: US17248W2044
CUSIP: 17248W105
